Peritoneal Dialysis (PD)ULIFT-PDNCT07437677
A Survey for Patients and Caregivers Aiming to Understand and Improve the Care of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis:
An observational study of Peritoneal Dialysis (PD) and Hemodialysis, run by Ciusss de L'Est de l'Île de Montréal.
Trial summary
Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Peritoneal Dialysis (PD), Hemodialysis, Kidney Replacement Therapy
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- Jan 2027to Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients with lived experience of peritoneal dialysis and transitions to hemodialysis, as well as caregivers of such patients, recruited from dialysis centers and patient communities across multiple centers.
Who may be able to join
- Adult (≥18 years)
- One of the following:
- Patient who experienced a PD-to-HD transition in past 12 months
- Patient currently receiving peritoneal dialysis
- Caregiver (self-defined, including spouses, family members, or friends) of individuals meeting the above criteria
- Able to read English or French
- Able to complete the survey in paper or web-based format
- Able to provide informed consent
Who cannot join
- Age <18 years
- Unable to provide consent
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis - Phase 2 (Survey)
Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients.
Overall, the UPLIFT-PD program aims to fill this gap by studying the transition from peritoneal dialysis to hemodialysis. The specific goal of this mixed methods sub-study is to conduct a national survey to ask patients and caregivers about priorities and preferences when they anticipate a transfer from peritoneal dialysis to hemodialysis. This survey will be co-created by patient-partners and dialysis experts.
Results from this survey will then be used in other phases of UPLIFT-PD program, detailed in other registrations, which will support people facing a transition from peritoneal dialysis to hemodialysis..
- Keywords
- Transfer to hemodialysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Survey Participants | Survey participants will include both patients (or their caregivers) having experienced a transition to hemodialysis in the past year or currently receiving peritoneal dialysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Priorities and Challenges Related to PD-to-HD Transitions
Measured using Likert-scale responses assessing perceived importance of transition-related factors (e.g. preparedness, timing of discussions, vascular access planning, psychosocial impact). Likert-scale from 0 (lowest importance) to 9 (highest importance)
Measured: At survey completion (Baseline)
Secondary outcomes (2)
Preferences for Clinical Scenarios Related to PD-to-HD Transitions
Assessed using a discrete choice experiment evaluating trade-offs between attributes such as duration on PD, risk of complications, and planned vs. unplanned HD transfer.
Measured: At survey completion (Baseline)
Perceptions of Successful Transition
Agreement with proposed definitions of successful PD-to-HD transitions based on care pathways.
Measured: At survey completion (Baseline)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study startJan 2027 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peritoneal Dialysis (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, Annie-Claire Nadeau-Fredette, Ciusss de L'Est de l'Île de Montréal
- Investigators
- Annie-Claire Nadeau-Fredette, MD MSc, Principal investigator, CIUSSS de l'Est-de-l'Ile de Montréal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07437677
- Sponsor's protocol ID
- 2026-4258
- Other IDs
- 203760_1
- Acronym
- ULIFT-PD
- Status last verified
- Feb 2026
- First submitted
- 20 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Considering the survey nature of the study and in compliance with our ethic board requirements
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis - Phase 2 (Survey)
- ClinicalTrials.gov ID
- NCT07437677
- Acronym / sponsor ID
- ULIFT-PD / 2026-4258
- Keywords
- Transfer to hemodialysis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Ciusss de L'Est de l'Île de MontréalUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- Jan 2027 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients.
Overall, the UPLIFT-PD program aims to fill this gap by studying the transition from peritoneal dialysis to hemodialysis. The specific goal of this mixed methods sub-study is to conduct a national survey to ask patients and caregivers about priorities and preferences when they anticipate a transfer from peritoneal dialysis to hemodialysis. This survey will be co-created by patient-partners and dialysis experts.
Results from this survey will then be used in other phases of UPLIFT-PD program, detailed in other registrations, which will support people facing a transition from peritoneal dialysis to hemodialysis..
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Survey Participants | – | –Survey participants will include both patients (or their caregivers) having experienced a transition to hemodialysis in the past year or currently receiving peritoneal dialysis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with lived experience of peritoneal dialysis and transitions to hemodialysis, as well as caregivers of such patients, recruited from dialysis centers and patient communities across multiple centers.
Key inclusion criteria (8 listed)
- Adult (≥18 years)
- One of the following:
- Able to read English or French
- Able to complete the survey in paper or web-based format
- Able to provide informed consent
Key exclusion criteria (2 listed)
- Age <18 years
- Unable to provide consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Priorities and Challenges Related to PD-to-HD Transitions
Time frame: At survey completion (Baseline)
Measured using Likert-scale responses assessing perceived importance of transition-related factors (e.g. preparedness, timing of discussions, vascular access planning, psychosocial impact). Likert-scale from 0 (lowest importance) to 9 (highest importance)
2 secondary outcomes
Preferences for Clinical Scenarios Related to PD-to-HD Transitions
Time frame: At survey completion (Baseline)
Perceptions of Successful Transition
Time frame: At survey completion (Baseline)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No. Considering the survey nature of the study and in compliance with our ethic board requirements
Related trials for Peritoneal Dialysis (PD)
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Not yet recruiting
Iodine Starch Test Use in Pleuroperitoneal Leak
Peritoneal Dialysis, Peritoneal Dialysis (PD)
RecruitingObservational study
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Kidney Disease, Peritoneal Dialysis (PD)
Recruiting
STarting incrEmental Prescription of Peritoneal Dialysis
Peritoneal Dialysis (PD), Kidney Failure
RecruitingObservational study
Peritoneal Dialysis Registration System (PERSIST)
ESRD, Disorders Associated With Peritoneal Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Annie-Claire Nadeau-Fredette, MD MSc principal investigator
CIUSSS de l'Est-de-l'Ile de Montréal
Questions about this trial
What is this clinical trial studying?
An observational study of Peritoneal Dialysis (PD) and Hemodialysis, run by Ciusss de L'Est de l'Île de Montréal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Annie-Claire Nadeau-Fredette, MD MSc (514-252-3400 ext. 6141, ac.nadeau-fredette@umontreal.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Priorities and Challenges Related to PD-to-HD Transitions (time frame: At survey completion (Baseline)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.